FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3159199688> ?p ?o ?g. }

• W3159199688 endingPage "653" @default.
• W3159199688 startingPage "637" @default.
• W3159199688 abstract "Patients experiencing relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) have limited treatment options and poor prognosis. Tisagenlecleucel (TIS) has shown improved clinical outcomes, but at a high upfront cost. Singapore has a multi-payer healthcare system where private insurance is one of the major payers. This study evaluated the cost-effectiveness and budget impact of TIS against salvage chemotherapy regimen (SCR) for treating r/r DLBCL patients who have failed ≥2 lines of systemic therapy from Singapore's private insurance payer's perspective.Over a life-time horizon, a partitioned survival model with three health-states was developed to evaluate the cost-effectiveness of TIS vs. SCR with or without hematopoietic stem cell transplantation (HSCT). Efficacy inputs for TIS and SCR were based on 43 months of observation data from pooled JULIET and UPenn trials, and CORAL extension studies respectively. Direct costs for pre-treatment, treatment, adverse events, follow-up, subsequent-HSCT, relapse, and terminal care were included. Incremental cost-effectiveness ratios (ICERs) were calculated as the total incremental costs per quality-adjusted life-year (QALY) gained. Additionally, the financial implication of introducing TIS in Singapore from a private payer's perspective was analyzed, comparing the current treatment pathway (without TIS) with a future scenario (with TIS) over 5 years.Compared with SCR, TIS was the dominant option, with cost savings of S$8,477 alongside an additional gain of 2.78 QALYs in privately insured patients who shifted from private to public hospitals for TIS treatment. Scenario analyses for patients starting in public hospitals show ICERs of S$99,623 (no subsidy) and S$133,261 (50% subsidy for SCR treatment, no subsidy for TIS), supporting the base case. The projected annual budget impact ranges from S$850,000 to S$3.4 million during the first 5 years.TIS for treating r/r DLBCL patients who have failed ≥2 lines of systemic therapies, is likely to be cost effective with limited budget impact." @default.
• W3159199688 created "2021-05-10" @default.
• W3159199688 creator A5007749861 @default.
• W3159199688 creator A5008909013 @default.
• W3159199688 creator A5028217264 @default.
• W3159199688 creator A5031927188 @default.
• W3159199688 creator A5038667383 @default.
• W3159199688 creator A5053034580 @default.
• W3159199688 creator A5057909346 @default.
• W3159199688 creator A5080656059 @default.
• W3159199688 date "2021-01-01" @default.
• W3159199688 modified "2023-10-01" @default.
• W3159199688 title "Cost-effectiveness and budget impact analyses of tisagenlecleucel in adult patients with relapsed or refractory diffuse large B-cell lymphoma from Singapore’s private insurance payer’s perspective" @default.
• W3159199688 cites W1909881665 @default.
• W3159199688 cites W1982967337 @default.
• W3159199688 cites W2018435653 @default.
• W3159199688 cites W2035098923 @default.
• W3159199688 cites W2064378168 @default.
• W3159199688 cites W2065749162 @default.
• W3159199688 cites W2076377855 @default.
• W3159199688 cites W2076408955 @default.
• W3159199688 cites W2102687941 @default.
• W3159199688 cites W2133345449 @default.
• W3159199688 cites W2136060045 @default.
• W3159199688 cites W2146461887 @default.
• W3159199688 cites W2150587745 @default.
• W3159199688 cites W2161245598 @default.
• W3159199688 cites W2167556523 @default.
• W3159199688 cites W2180615187 @default.
• W3159199688 cites W2261890054 @default.
• W3159199688 cites W2305142474 @default.
• W3159199688 cites W2523392153 @default.
• W3159199688 cites W2567289819 @default.
• W3159199688 cites W2744261860 @default.
• W3159199688 cites W2765198305 @default.
• W3159199688 cites W2775369717 @default.
• W3159199688 cites W2810179171 @default.
• W3159199688 cites W2903062212 @default.
• W3159199688 cites W2906002519 @default.
• W3159199688 cites W2919538398 @default.
• W3159199688 cites W2920959584 @default.
• W3159199688 cites W2948047060 @default.
• W3159199688 cites W2982990394 @default.
• W3159199688 cites W2984375644 @default.
• W3159199688 cites W2986264979 @default.
• W3159199688 cites W2991246146 @default.
• W3159199688 cites W3001823821 @default.
• W3159199688 cites W3037293601 @default.
• W3159199688 cites W3047541106 @default.
• W3159199688 cites W3048509056 @default.
• W3159199688 cites W3135175412 @default.
• W3159199688 doi "https://doi.org/10.1080/13696998.2021.1922066" @default.
• W3159199688 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33904359" @default.
• W3159199688 hasPublicationYear "2021" @default.
• W3159199688 type Work @default.
• W3159199688 sameAs 3159199688 @default.
• W3159199688 citedByCount "6" @default.
• W3159199688 countsByYear W31591996882022 @default.
• W3159199688 countsByYear W31591996882023 @default.
• W3159199688 crossrefType "journal-article" @default.
• W3159199688 hasAuthorship W3159199688A5007749861 @default.
• W3159199688 hasAuthorship W3159199688A5008909013 @default.
• W3159199688 hasAuthorship W3159199688A5028217264 @default.
• W3159199688 hasAuthorship W3159199688A5031927188 @default.
• W3159199688 hasAuthorship W3159199688A5038667383 @default.
• W3159199688 hasAuthorship W3159199688A5053034580 @default.
• W3159199688 hasAuthorship W3159199688A5057909346 @default.
• W3159199688 hasAuthorship W3159199688A5080656059 @default.
• W3159199688 hasBestOaLocation W31591996881 @default.
• W3159199688 hasConcept C112930515 @default.
• W3159199688 hasConcept C126322002 @default.
• W3159199688 hasConcept C2777408962 @default.
• W3159199688 hasConcept C2778559949 @default.
• W3159199688 hasConcept C2779338263 @default.
• W3159199688 hasConcept C2781413609 @default.
• W3159199688 hasConcept C2911091166 @default.
• W3159199688 hasConcept C3019080777 @default.
• W3159199688 hasConcept C71924100 @default.
• W3159199688 hasConceptScore W3159199688C112930515 @default.
• W3159199688 hasConceptScore W3159199688C126322002 @default.
• W3159199688 hasConceptScore W3159199688C2777408962 @default.
• W3159199688 hasConceptScore W3159199688C2778559949 @default.
• W3159199688 hasConceptScore W3159199688C2779338263 @default.
• W3159199688 hasConceptScore W3159199688C2781413609 @default.
• W3159199688 hasConceptScore W3159199688C2911091166 @default.
• W3159199688 hasConceptScore W3159199688C3019080777 @default.
• W3159199688 hasConceptScore W3159199688C71924100 @default.
• W3159199688 hasIssue "1" @default.
• W3159199688 hasLocation W31591996881 @default.
• W3159199688 hasLocation W31591996882 @default.
• W3159199688 hasOpenAccess W3159199688 @default.
• W3159199688 hasPrimaryLocation W31591996881 @default.
• W3159199688 hasRelatedWork W1986713097 @default.
• W3159199688 hasRelatedWork W2050719878 @default.
• W3159199688 hasRelatedWork W2065856818 @default.
• W3159199688 hasRelatedWork W2089045987 @default.
• W3159199688 hasRelatedWork W2146126563 @default.
• W3159199688 hasRelatedWork W29179590 @default.

• next